TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11233804

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g i.v. every 8 hours
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ceftazidime 2 g i.v. every 8 hours plus Amikacin 15 mg/kg daily
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ceftazidime/Amikacin
Number of subjects: 140
Study: 9850361

Group type: EXPERIMENTAL
Intervention: HFA-BDP (0, 200, 400 or 800 micrograms day-1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CFC-BDP (800 micrograms day-1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HFA-BDP (400 micrograms day-1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CFC-BDP (1500 micrograms day-1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HFA-BDP (up to 800 micrograms day-1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CFC-BDP
Number of subjects: 43
Study: 7501332

Group type: EXPERIMENTAL
Intervention: Vaginal PGE2 gel (2 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal PGE2 tablet (3 mg)
Number of subjects: 200
Study: 2169703

Group type: EXPERIMENTAL
Intervention: Calcium and cholecalciferol supplementation (1000 mg Ca/d and 1000 IU cholecalciferol/d)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 7214297

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy for periods of 9.4 +/- 1.7 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: No BCG immunotherapy (control group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study: 31529935

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 12338

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 12338

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 12338

Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 12338

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 12338

Group type: EXPERIMENTAL
Intervention: Cardiovascular Diseases (CVD) prevalence
Number of subjects: 12338

Group type: EXPERIMENTAL
Intervention: Risk factors associated with CVD
Number of subjects: 12338
Study: 28327694

Group type: EXPERIMENTAL
Intervention: SurfLink-treated titanium dental implants
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untreated control titanium dental implants
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both SurfLink and control implants
Number of subjects: 23
Study: 26318757

Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy using oesophageal Doppler during surgery
Number of subjects: 0
Study: 24371255

Group type: EXPERIMENTAL
Intervention: A(H3N2) viruses classified as homologous to the vaccine strains based on HA1 domain nucleic acid sequence
Number of subjects: 43000

Group type: EXPERIMENTAL
Intervention: A(H1N1) viruses classified as homologous to the vaccine strains based on HA1 domain nucleic acid sequence
Number of subjects: 43000

Group type: EXPERIMENTAL
Intervention: PCR subtyping for A(H3N2) and A(H1N1) viruses
Number of subjects: 43000

Group type: EXPERIMENTAL
Intervention: HA1 sequence analysis
Number of subjects: 43000
Study: 22555886

Group type: EXPERIMENTAL
Intervention: Interdisciplinary program of geriatric consultation, in-hospital and at-home rehabilitation, and discharge planning (n = 80)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual care (n = 82)
Number of subjects: 162
Study: 20011757

Group type: EXPERIMENTAL
Intervention: Fluoride-containing dentifrice (NaF dentifrice) on a toothbrush for 60 s twice a day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Unwaxed dental floss twice a day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Waxed dental floss twice a day in every interproximal space
Number of subjects: 32

Group type: COMPARATOR
Intervention: Drinking water rinsing twice a day for 60 s
Number of subjects: 32
Study: 17142825

Group type: EXPERIMENTAL
Intervention: 5 u of oxytocin as a bolus injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5 u of oxytocin as an infusion over 5 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (bolus and infusion)
Number of subjects: 30
Study: 15107384

Group type: EXPERIMENTAL
Intervention: Rapid dosing regimen (10 mg over 30 seconds, repeated once after three minutes if pain score remained above three)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cautious dosing regimen (5 mg over two minutes, repeated at three minute intervals if pain score remained above three to a maximum dose of 20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid dosing regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cautious dosing regimen
Number of subjects: 0
Study: 11454114

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 28
Study: 9630259

Group type: EXPERIMENTAL
Intervention: Group 1 (treatment for 4 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group 2 (4 months without treatment followed by 4 months of treatment)
Number of subjects: 30
Study: 8001718

Group type: EXPERIMENTAL
Intervention: Maltitol solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maltitol chocolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucrose solution (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucrose containing chocolate (control)
Number of subjects: 0
Study: 2220638

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 46
Study: 671428

Group type: EXPERIMENTAL
Intervention: Acupuncture at theoretically appropriate locations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupuncture at theoretically inappropriate locations
Number of subjects: 0
Study: 31819017

Group type: EXPERIMENTAL
Intervention: Molecular profiling using candidate gene specific primers (14 candidate genes, 12 reported and 14 designed primer pairs)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single marker analysis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Molecular analysis based on candidate genes specific primers
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hierarchical classification and principal co‐ordinate analysis
Number of subjects: 28
Study: 26489973

Group type: EXPERIMENTAL
Intervention: Immediate Rotational Atherectomy (RA)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Delayed Rotational Atherectomy (RA)
Number of subjects: 198
Study: 23821328

Group type: EXPERIMENTAL
Intervention: CarboRT (carboplatin 100 mg/m2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: CisRT (cisplatin 40 mg/m2)
Number of subjects: 51
Study: 22112202

Group type: EXPERIMENTAL
Intervention: 36‐ingredient micronutrient formula (mainly vitamins and minerals) consumed over an 8‐week period
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group of 14 non‐ADHD adults not taking the formula
Number of subjects: 14
Study: 19125120

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25[OH]D) concentration
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Musculoskeletal symptoms (muscle pain in neck and back)
Number of subjects: 29
Study: 17091139

Group type: EXPERIMENTAL
Intervention: G1 (IntenS with hard polymerization)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: G2 (IntenS with soft polymerization)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: G3 (Filtek flow)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: G4 (Fuji II LC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: G1, G2, G3
Number of subjects: 14

Group type: COMPARATOR
Intervention: G1=G2
Number of subjects: 14

Group type: COMPARATOR
Intervention: G1=G2=G3
Number of subjects: 14
Study: 14751362

Group type: COMPARATOR
Intervention: Chemotherapy (estramustine 140 mg three times daily and etoposide 100 mg orally for 21 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of somatostatin analog (lanreotide 30 mg intramuscularly every 14 days) and dexamethasone (4 mg tapered to 1 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 40
Study: 11599647

Group type: EXPERIMENTAL
Intervention: 20 mg of fluoxetine daily
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 60 mg of fluoxetine weekly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 15613168

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Desipramine 75 mg
Number of subjects: 37
Study: 7929683

Group type: EXPERIMENTAL
Intervention: Phonemic inventories of children with phonological delays
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phonetic inventories of children with phonological delays
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cross-sectional results
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Theoretical implications of phonemic acquisition
Number of subjects: 30
Study: 2974255

Group type: EXPERIMENTAL
Intervention: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atracurium administered by winged needle in the antecubital fossa with flushing after thiopentone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atracurium administered by winged needle in the antecubital fossa without flushing
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atracurium administered by winged needle in the dorsum of the hand without flushing
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atracurium maintained at room temperature for at least 2 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa (subgroup of patients with drug allergy)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa (subgroup of patients aged over 70 years)
Number of subjects: 150
Study: 5328328

Group type: EXPERIMENTAL
Intervention: quinethazone 50 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: chlorothiazide 500 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: lactose placebo
Number of subjects: 27
Study: 31912268

Group type: EXPERIMENTAL
Intervention: Laser hemorrhoidoplasty (LHP)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Sutured mucopexy (MP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Excisional hemorrhoidectomy (EH)
Number of subjects: 121
Study: 29762642

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Number of subjects: 152
Study: 28238301

Group type: EXPERIMENTAL
Intervention: Hemocoagulase agkistrodon (n=48)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (n=48)
Number of subjects: 96
Study: 25264753

Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg)
Number of subjects: 25
Study: 23450513

Group type: EXPERIMENTAL
Intervention: 40 mg sildenafil, 3 times per day for 9 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparable placebo
Number of subjects: 70
Study: 21276190

Group type: EXPERIMENTAL
Intervention: Gua sha
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (local thermal heat pad)
Number of subjects: 48
Study: 19076108

Group type: EXPERIMENTAL
Intervention: Paracetamol + Pregabalin + Dexamethasone
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Paracetamol + Pregabalin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Paracetamol + Placebo
Number of subjects: 116
Study: 16757158

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once a day for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 10
Study: 15522707

Group type: EXPERIMENTAL
Intervention: Adults with myotonic dystrophy (MD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with sleep apnoea syndrome (SAS)
Number of subjects: 0
Study: 10899450

Group type: EXPERIMENTAL
Intervention: Post-exercise recovery of phosphocreatine in Friedreich ataxia patients after ischemic exercise.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time constants of recovery of phosphocreatine.
Number of subjects: 0
Study: 9200172

Group type: EXPERIMENTAL
Intervention: Hydromorphone 10 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydromorphone 20 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydromorphone 40 micrograms/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study: 8440860

Group type: EXPERIMENTAL
Intervention: High intensity progressive resistance training of the hip and knee extensors 3 days per week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplementation with a 360-kcal high carbohydrate, low fat liquid supplement every day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of high intensity progressive resistance training and multi-nutrient supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid placebo every day (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leisure activities (non-exercising groups)
Number of subjects: 0
Study: 3758471

Group type: EXPERIMENTAL
Intervention: Toothpaste containing nicomethanol hydrofluoride
Number of subjects: 76

Group type: COMPARATOR
Intervention: Toothpaste containing potassium nitrate and sodium monofluorophosphate
Number of subjects: 76
Study: 31884902

Group type: EXPERIMENTAL
Intervention: High-intensity stepping intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 30144938

Group type: EXPERIMENTAL
Intervention: 12-month PA coaching intervention (Walk On!)
Number of subjects: 2707

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2707
Study: 27460746

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol only (control group)
Number of subjects: 120
Study: 25027174

Group type: EXPERIMENTAL
Intervention: Completely anonymous survey condition
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: $20 incentive
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Intermediate privacy condition
Number of subjects: 324
Study: 22718030

Group type: COMPARATOR
Intervention: Whey protein 0 g (Control)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Whey protein 10 g
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Whey protein 20 g
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Whey protein 30 g
Number of subjects: 327
Study: 21188316

Group type: EXPERIMENTAL
Intervention: Multidisciplinary program intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 37
Study: 18986069

Group type: EXPERIMENTAL
Intervention: Transparency interpretation possible with unrestrained presentation times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transparency interpretation inhibited by occluding local junctions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transparency interpretation possible with short presentation times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unambiguous stimulus displays without specific attentional instructions
Number of subjects: 0
Study: 15936361

Group type: EXPERIMENTAL
Intervention: PEEK cage containing a biphasic calcium phosphate ceramic (Triosite)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PEEK cage containing an autogenous iliac bone graft
Number of subjects: 100
Study: 12950521

Group type: EXPERIMENTAL
Intervention: Combined antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticoagulation therapy with warfarin
Number of subjects: 0
Study: 10394282

Group type: EXPERIMENTAL
Intervention: Stabilizing exercise (n = 15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Mobilizing exercise (n = 12)
Number of subjects: 27
Study: 8744104

Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms/day for 6 months)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 11
Study: 1906161

Group type: EXPERIMENTAL
Intervention: Tobramycin administered every 6 hours
Number of subjects: 34

Group type: COMPARATOR
Intervention: Tobramycin administered every 8 hours
Number of subjects: 34
Study: 6504709

Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomers (‐2.5/+80 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomers (‐5/+80 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomers (‐10/+80 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30020447

Group type: COMPARATOR
Intervention: 3 days of oral azithromycin (A3)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 3 days of oral doxycycline (D3)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 7 days of oral doxycycline (D7)
Number of subjects: 216
Study: 30043524

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 2.0 mg
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Individualized treatment regimens
Number of subjects: 1524
Study: 26807718

Group type: EXPERIMENTAL
Intervention: Anti-oxidative therapy (pravastatin 40 mg/d and vitamin E 300 mg/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (no anti-oxidants)
Number of subjects: 62
Study: 24972936

Group type: EXPERIMENTAL
Intervention: Large volume low pressure nasal saline + fluticasone propionate (3 weeks)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard therapy (antibiotherapy + nasal decongestant) (2 weeks)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 22170366

Group type: EXPERIMENTAL
Intervention: CSB++ (75 kcal/kg/day)
Number of subjects: 2612

Group type: COMPARATOR
Intervention: Soy RUSF
Number of subjects: 2612

Group type: COMPARATOR
Intervention: Soy/whey RUSF
Number of subjects: 2612
Study: 20682669

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 4.5 g/night
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 6 g/night
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 17435611

Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC) (100 mg elemental iron)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ferrous sulphate (FS) (120 mg elemental iron)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ferrous sulphate (FS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cost of treatment
Number of subjects: 100
Study: 15590762

Group type: EXPERIMENTAL
Intervention: Theophylline (loading dose of 4 mg/kg IV over 30 min, followed by 0.4 mg/kg/min for at least 6 hours, then 350 mg orally three times daily for 4 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (administered in control arm)
Number of subjects: 0
Study: 14565810

Group type: EXPERIMENTAL
Intervention: Sulfonylureas (tolazamide, glyburide, glipizide GITS, glimepiride) with insulin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Glimepiride with insulin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sulfonylureas with insulin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 40
Study: 10395630

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg per day
Number of subjects: 341

Group type: COMPARATOR
Intervention: Angioplasty followed by usual care
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 341
Study: 8908821

Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day for one month, then 200 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 76
Study: 1909085

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (2 L daily of 3.5% crystalline amino acids in 5% dextrose) plus standard therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oxandrolone (20 mg orally four times a day) plus standard therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of oxandrolone and nutritional supplementation plus standard therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard therapy (abstinence, balanced diet, multivitamins)
Number of subjects: 39
Study: 7060255

Group type: EXPERIMENTAL
Intervention: Hyaluronidase, 500 IU/kg i.v., every 6 hours for 42 hours
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hyaluronidase, 500 IU/kg i.v., every 6 hours for 42 hours (among 21 patients treated within 6 hours of onset)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hyaluronidase and Placebo
Number of subjects: 48
Study: 31981558

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (approximately 20 mg per kg of bodyweight)
Number of subjects: 40375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40375
Study: 30296721

Group type: EXPERIMENTAL
Intervention: Boston Summer Youth Employment Program (SYEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28501886

Group type: EXPERIMENTAL
Intervention: Mixed visible and ultraviolet (UVA and UVB) light source application (mUV/VIS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Visible light alone (placebo)
Number of subjects: 50
Study: 25377762

Group type: EXPERIMENTAL
Intervention: Infant crying (10 minutes)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Infant cooing (10 minutes)
Number of subjects: 98
Study: 23661689

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 5249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 5249

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 5249
Study: 20553131

Group type: EXPERIMENTAL
Intervention: Titanium healing abutments
Number of subjects: 16

Group type: COMPARATOR
Intervention: Polymer healing abutments
Number of subjects: 16
Study: 19481808

Group type: EXPERIMENTAL
Intervention: AcrySof phakic angle-supported intraocular lens (IOL) implantation
Number of subjects: 190